Navigation Links
LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System
Date:11/16/2007

BURLINGTON, Mass., Nov. 16 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) today announced the commercial launch of the TT(TM) Tortuous Tracker Delivery System, the next-generation introducer for LeMaitre Vascular's EndoFit(R) and UniFit(TM) Aortic Stent Graft product lines. The new delivery system will be sold beginning on Monday, November 19th, in the European Union and other select markets outside of the United States.

The TT system is designed to simplify stent graft implants by requiring reduced deployment force, providing the physician with increased control over placement of the stent graft in the aorta. The TT system offers better flexibility and an improved coating to increase maneuverability through blood vessels and a three-part valve system to minimize blood loss during the medical procedure. The TT system also provides better visualization during the procedure and a more ergonomic design.

"The TT system should improve the ease of use and therefore the performance of our endovascular stent grafts," said Ryan Connelly, Director, Research & Development of LeMaitre Vascular. "Since we acquired our stent graft product lines in 2005, we have carefully studied what vascular surgeons need to successfully deliver and deploy aortic stent grafts. The new TT system gives them what they have been asking for, which will enable better clinical results and improve patients' lives."

The TT system has already been used by physicians in over a dozen procedures designed to provide the company with pre-launch clinical feedback.

"I was very pleased with the flexibility of the device and its ability to navigate tortuous vessels," said Thomas Larzon, MD, Director of the EndoVascular Unit at Orebro University Hospital in Sweden. "It took much less physical effort to deploy the stent graft, which meant that I could more precisely position the stent graft where it would provide the best outcome for the patient."

"We are pleased to be able to offer a delivery system that we believe meets the high performance standards set by our stent graft products," said George W. LeMaitre, Chairman and CEO of LeMaitre Vascular. "We believe that the prior generation delivery system had discouraged adoption of our stent grafts. The TT system removes this impediment to growth."

The TT system will initially be available in a limited range of sizes as the company scales its production, with all sizes expected to become available by the end of 2008.

LeMaitre Vascular will be hosting its first ever Analyst Day at the Marriott Marquis Hotel in New York City, on Monday, November 19th. Management, along with vascular surgeon customers, will be giving an overview and update on the Company and its products, including the new TT Tortuous Tracker Delivery System. A live audio webcast of the presentation will be available via the Internet at http://www.lemaitre.com/investor and will be available for replay for 30 days.

The TT Tortuous Tracker Delivery System and the EndoFit and UniFit Aortic Stent Grafts are not approved for sale in the United States.

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures, and markets medical devices for the treatment of peripheral vascular disease. The company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803.

Certain statements set forth above that are not clearly historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the future clinical performance of the TT Tortuous Tracker Delivery System and the impact that the device may have on LeMaitre Vascular's growth. Although LeMaitre Vascular believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, these forward-looking statements are neither promises nor guarantees. LeMaitre Vascular's business is subject to significant risks and uncertainties and there can be no assurance that its actual results will not differ materially from its expectations. These risks and uncertainties include, among others: the risk that the TT Tortuous Tracker Delivery System fails to provide the desired safety and efficacy following the commercial launch or is not accepted by the market for other reasons; the risk that LeMaitre Vascular cannot adequately effectively manufacture all necessary sizes of the device or scale up production at reasonable costs; and other risk factors that are discussed in LeMaitre Vascular's Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. The forward-looking statements made in this release are made only as of the date hereof and LeMaitre Vascular disclaims any intention or responsibility for updating predictions or expectations contained in this release.


'/>"/>
SOURCE LeMaitre Vascular, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. LeMaitre Vascular to Start Italian Sales Force
2. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
3. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
4. LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
5. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
6. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
7. Pot bellies linked to early signs of cardiovascular disease
8. Air pollution linked to cardiovascular risk indices in healthy young adults
9. Environmental stress probed in cardiovascular disease, diabetes
10. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
11. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with ... new study from the Osteoarthritis Initiative shows that certain people who experience ... this in advance may give doctors the opportunity to treat patients before the problem ...
(Date:5/26/2017)... ... , ... Amir Qureshi, MD is the first physician in Arkansas to implant ... The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for ... to introduce the most powerful SCS system and the only stretchable lead on the ...
(Date:5/26/2017)... MA (PRWEB) , ... May 26, 2017 , ... On ... Act (AHCA), which narrowly passed the U.S. House on May 4, would result in ... be expected under continued implementation of the 2010 Patient Protection and Affordable Care Act ...
(Date:5/26/2017)... San Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... San Francisco, is proud to announce a new, informational blog post on insurance options. ... tooth surgery, checking insurance plans may help save time and money. Visiting an in-network ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: ... many others. “Cactus Jack: Against All Odds” is the creation of published author, ... Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 ... 2017 Annual Clinical and Scientific Meeting— OBP Medical , ... devices, today announced the launch of a new extra-small ... and ER-SPEC vaginal specula. Already available ... and extra-large sizes makes OBP Medical,s line of single-use ...
(Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
Breaking Medicine Technology: